

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 May 2006 (04.05.2006)

PCT

(10) International Publication Number
WO 2006/046105 A1

(51) International Patent Classification:

A61K 31/55 (2006.01) A61K 9/48 (2006.01)
A61K 9/16 (2006.01) A61K 9/08 (2006.01)
A61K 9/20 (2006.01) A61K 9/10 (2006.01)
A61K 9/28 (2006.01) A61P 25/08 (2006.01)

(21) International Application Number:

PCT/IB2005/003168

(22) International Filing Date: 24 October 2005 (24.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2084/DEL/2004 25 October 2004 (25.10.2004) IN

(71) Applicant (for all designated States except US): **RAN-BAXY LABORATORIES LIMITED** [IN/IN]; Plot No. 90, Sector - 32, Gurgaon, Haryana 122001 (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SINGLA, Ajay, Kumar** [IN/IN]; House No. 409, Sector 20A, Chandigarh 160020 (IN). **ARORA, Sachin** [IN/IN]; House No. 55 Kaziyan Street, Muzaffarnagar, Uttar Pradesh 166020 (IN). **DABRE, Rahul** [IN/IN]; C-25, First Floor, Southend Floor, Gurgaon, Haryana 122001 (IN).

(74) Common Representative: **RANBAXY LABORATORIES LIMITED**; c/o DESHMUKH, Jay, R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: OXCARBAZEPINE DOSAGE FORMS

(57) Abstract: The present invention relates to dosage forms of oxcarbazepine for oral administration that contain oxcarbazepine having a median particle size of from about 14 μm to about 30 μm and to processes for the preparation of such dosage forms. The dosage form may be a solid or a liquid dosage form. The solid dosage form may be in the form of a tablet, a capsule, or a granulate. The liquid dosage form may be in the form of a solution or a suspension.

WO 2006/046105 A1

OXCARBAZEPINE DOSAGE FORMS

Field of the Invention

The present invention relates to dosage forms of oxcarbazepine for oral administration and to processes for the preparation of such dosage forms.

Background of the Invention

Drug insolubility is one of the major challenges in the development of many pharmaceutical products. Over one third drugs listed in the US Pharmacopoeia and about fifty percent of New Chemical Entities are insoluble or poorly soluble in water. The result is that many drugs are marketed as sub-optimal formulations, which after administration lead to poor or erratic bioavailability or a greater risk of adverse side effects. Oxcarbazepine, 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide, a widely used antiepileptic drug has poor solubility in water.

One of the earlier attempts to enhance the dissolution rate and bioavailability of oxcarbazepine relied on particle size reduction of the oxcarbazepine to an order of 2 to 12 μm . International (PCT) Publication No. WO 98/35681 discloses a composition of oxcarbazepine for oral administration employing micronized drug particles of 2 to 12 μm ranges.

Oxcarbazepine tablets are also known to undergo a color change during storage. The discoloration is caused by the formation of a minor amount of an oxidation product "diketoiminodibenzyl", 10, 11-dihydro-5H-dibenzo [b,f] azepine-10,11-dione. This oxidation product is considered to be pharmacologically harmless. However, the color change is not generally pharmaceutically desirable.

U.S. Patent Nos. 5,472,714 and 5,695,782 describe color stable oxcarbazepine tablets. The color stability has been achieved by providing double coating to the tablets. Oxcarbazepine tablets described therein are provided with hydrophilic, permeable inner layer containing white pigments and further a hydrophilic, permeable outer layer containing white pigments in combination with iron (II) oxide pigments.

Our International (PCT) Publication No. WO 02/094774, which is hereby incorporated by reference, discloses an oxcarbazepine formulation comprising oxcarbazepine and a wetting agent.

Summary of the Invention

In one general aspect there is provided dosage forms that include oxcarbazepine having a median particle size of from about 14 μm to about 30 μm . In particular, the median particle size may be from about 14 μm to about 25 μm .

The dosage form may be a solid or a liquid dosage form. The solid dosage form may be in the form of a tablet, a capsule, or a granulate. The liquid dosage form may be in the form of a solution or a suspension.

Embodiments of the dosage form may include one or more of the following features. For example, the solid dosage form may further include one or more pharmaceutically acceptable excipients that include surfactants, diluents, binders, disintegrants, lubricants, glidants, and coloring agents. The liquid dosage form may further include one or more pharmaceutically acceptable excipients that include surfactants, diluents, binders, disintegrants, lubricants, glidants, and coloring agents.

In another general aspect there is provided a process for preparing a solid dosage form of oxcarbazepine. The process includes mixing the oxcarbazepine having a median particle size of from about 14 μm to about 30 μm with other pharmaceutical excipients to form a blend and forming the blend into a solid dosage form.

Embodiments of the process may include one or more of the following features. For example, in the process, shaping of the blend into a solid dosage form may include forming a tablet, capsule, or granulate.

The mixing may be one or more of wet granulation, dry granulation, and direct compression. The solid dosage form may include one or more pharmaceutically acceptable excipients selected from surfactants, diluents, binders, disintegrants, lubricants, glidants, and coloring agents.

In another general aspect there is provided a process for preparing a liquid dosage form of oxcarbazepine. The process includes dispersing a suspending agent and oxcarbazepine having a median particle size of from about 14 μm to about 30 μm ; and homogenizing. The suspending agent may be one or more of polysaccharides, a mixture of cellulose and xanthan gum, a mixture of polyethylene glycol and sodium carboxymethyl cellulose, a mixture of xanthan gum and pregelatinized starch, a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose (Avicel RC 591), and dispersed silicon dioxide (Aerosil 200).

Embodiments of the process may include one or more of the following features. For example, the dosage form may further include one or more pharmaceutically acceptable excipients that include surfactants, diluents, binders, disintegrants, lubricants, glidants, and coloring agents.

In another general aspect there is provided a method of treating partial seizures in adults with epilepsy and as an adjunct therapy for treating partial seizures in children ages 4-16 with epilepsy. The method includes orally administering to a human in need thereof a dosage form that includes the oxcarbazepine having a median particle of from about 14 μm to about 30 μm .

Embodiments of the dosage form may include one or more of the following features. For example, the solid dosage form may further include one or more pharmaceutically acceptable excipients that include surfactants, diluents, binders, disintegrants, lubricants, glidants, and coloring agents. The liquid dosage form may further include one or more pharmaceutically acceptable excipients that include surfactants, diluents, binders, disintegrants, lubricants, glidants, and coloring agents.

The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.

Detailed Description of the Invention

We have now discovered that stable and bioequivalent oxcarbazepine dosage forms can be prepared with oxcarbazepine having a median particle size of from about 14 μm to about 30 μm .

Oxcarbazepine, 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide is an agent of first choice in the treatment of convulsions. The known dosage forms, such as tablets and liquid dosage forms, for example suspensions, are suitable for ensuring a uniform concentration of active ingredient in the blood, especially in the case of regularly recurring administration over a prolonged period of treatment.

The known particle size analysis methods are suitable for determining the median particle size, for example particle size measurement using light, for example light-scattering methods or turbidimetric methods, sedimentation methods, for example pipette analysis using an Andreassen pipette, sedimentation scales, photosedimentometers or sedimentation in a centrifugal force field, pulse methods, for example using a Coulter counter, or sorting by means of gravitational or centrifugal force.

In order to produce oxacarbazepine particles, for example crystals having the desired particle size, conventional comminution and de-agglomeration techniques may be used, for example grinding in an air-jet mill or impact mill, a ball mill, vibration mill, mortar mill or pin mill.

The pharmaceutically acceptable excipients may be selected from one or more of surfactants, diluents, binders, disintegrants, lubricants, glidants, suspending agents, solvents, antioxidants, preservatives, coloring agents, flavoring agents and sweeteners, which are chemically and physically compatible with oxcarbazepine.

The surfactant may be selected from anionic, cationic or non-ionic surface-active agents or surfactants. Suitable anionic surfactants include those containing carboxylate, sulfonate, and sulfate ions such as sodium lauryl sulfate (SLS), sodium laurate, dialkyl sodium sulfosuccinates particularly bis-(2-ethylhexyl) sodium sulfosuccinate, sodium stearate, potassium stearate, sodium oleate and the like. Suitable cationic surfactants include those containing long chain cations, such as benzalkonium chloride, bis-2-

hydroxyethyl oleyl amine or the like. Suitable non-ionic surfactants include polyoxyethylene sorbitan fatty acid esters, fatty alcohols such as lauryl, cetyl and stearyl alcohols; glyceryl esters such as the naturally occurring mono-, di-, and tri-glycerides; fatty acid esters of fatty alcohols; polyglycolized glycerides such as Gelucire; polyoxyethylene-polyoxypropylene block co-polymer such as Poloxamer and other alcohols such as propylene glycol, polyethylene glycol, sorbitan, sucrose, and cholesterol.

Diluents may be selected from any such pharmaceutically acceptable excipients that gives bulk to the oxcarbazepine composition and improves compressibility. For example, preferable diluents include one or more of calcium carbonate, calcium phosphate-dibasic, calcium phosphate-tribasic, calcium sulfate, cellulose-microcrystalline, cellulose powdered, dextrates, dextrans, dextrose excipients, fructose, kaolin, lactitol, lactose, mannitol, sorbitol, starch, starch pregelatinized, sucrose, sugar compressible, or sugar confectioners.

Binders may be selected from any pharmaceutically acceptable excipients that have cohesive properties to act as a binder. For example, preferably excipients include one or more of methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, gelatin, gum arabic, ethyl cellulose, polyvinyl alcohol, pregelatinized starch, agar, tragacanth, sodium alginate, or propylene glycol.

The disintegrant may be selected from, for example, one or more of starches or modified starches such as starch, modified starch, croscarmellose sodium, crospovidone and sodium starch glycolate. Other suitable disintegrants also may be used separately or in combination.

Lubricants may be selected from, for example, one or more of colloidal silicon dioxide, stearic acid, magnesium stearate, calcium stearate, talc, hydrogenated vegetable oil, sucrose esters of fatty acid, microcrystalline wax, yellow beeswax, white beeswax, glyceryl monostearate, and PEG 4000. Other suitable lubricants also may be used separately or in combination.

Glidants may be selected from, for example, colloidal silicon dioxide and talc, although any other suitable glidants may be used.

Suspending agents may be selected from, for example, one or more of polysaccharides, a mixture of cellulose and xanthan gum, a mixture of polyethylene glycol and sodium carboxymethyl cellulose, a mixture of xanthan gum and pregelatinized starch, a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose (Avicel RC 591), or dispersed silicon dioxide (Aerosil 200). The polysaccharides can be selected from one or more of tragacanth, xanthan gum, bentonite, acacia and lower alkyl ethers of cellulose including the hydroxy and carboxy derivatives of the cellulose ethers.

The dosage form may further include antioxidants to protect the oxcarbazepine from oxidative degradation. The antioxidants may be selected from, for example, ascorbic acid, sodium pyrosulphite, glutathion or sorbic acid.

The suspension for oral administration is usually aqueous based. The term "aqueous based" as used herein includes suspensions comprising water, or water and one or more of water-miscible solvents. Suitable water miscible solvents include, but not limited to, propylene glycol, polyethylene glycol, ethanol and other commonly used solvents known to the skilled in the art. These solvents also act as solvents for preservatives.

Examples of preservatives include propylparaben, methylparaben, and sorbic acid, sodium benzoate, or sodium bisulphate.

Coloring agents may be selected from any colorant used in pharmaceuticals that is approved and certified by the FDA. It may include Iron oxide, Lake of Tartrazine, Lake of Quinoline Yellow, Lake of Sunset Yellow and Lake of Erythrosine, Lack of Carmosine Ponceau, Allura Red.

Sweeteners may be selected from sucrose, lactose, glucose, aspartame, saccharine, or sorbitol solution.

Examples of suitable flavoring agents include yellow plum lemon, aroma, peppermint oil, oil of wintergreen, cherry, orange or raspberry flavoring.

The dosage forms that include oxcarbazepine, and other excipients include tablets, caplets, capsules, granules, suspension and solution. The dosage forms of oxcarbazepine

can be conveniently prepared by any of the methods known to those skilled in the art. For tablets, the method of choice may be wet granulation, dry granulation or direct compression. These methods include the basic step of intimately mixing the oxcarbazepine having a median particle size of from about 14 μm to about 30 μm with other pharmaceutically acceptable excipients and shaping the product into a solid dosage form. Alternatively, the wet granulation may be carried out by granulating fluid or a solution or dispersion of surfactant or solution or suspension of binder.

The granulating liquid can be, but is not limited to, water, ethanol, isopropyl alcohol, acetone, dichloromethane, and the like. Alternatively, the binder can be dissolved in the granulating liquid and used as a solution/dispersion.

The tablet dosage form may optionally be coated with functional and/or non-functional layers comprising film-forming polymers. The coating composition may include polymers and other coating additives.

Examples of film-forming polymers include ethylcellulose, hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, carboxymethyl cellulose, hydroxymethylcellulose, hydroxyethylcellulose, cellulose acetate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate; waxes such as polyethylene glycol; methacrylic acid polymers such as Eudragit® RL and RS; and the like. Alternatively, commercially available coating compositions comprising film-forming polymers marketed under various trade names, such as Opadry® may also be used for coating.

Coating additives may be selected from, for example, plasticizers, coloring agents, gloss producer, lubricants/glidants.

Polymer solution or dispersion may be prepared in various solvents such as water, ethanol, methanol, isopropyl alcohol, chloroform, acetone, ether or mixtures thereof. The coating composition can be coated onto solid dosage form using techniques such as spray coating in conventional coating pan or fluidized bed processor, or dip coating.

The invention described herein is further illustrated by the following examples, which should not be construed as limiting the scope of the invention.

Example 1:

Ingredient	Quantity
	(mg/unit)
Oxcarbazepine (Median particle size 20.86 μm)	600.0
Microcrystalline cellulose	131.2
Hydroxypropyl methyl cellulose	16.8
Cross-linked polyvinylpyrrolidone	40.0
Colloidal silicon dioxide	3.2
Magnesium stearate	8.8
Total	800.0

Process:

1. Microcrystalline cellulose (about half the quantity) and hydroxy propyl methylcellulose were sifted through sieve; and mixed with oxcarbazepine for about 10 minutes to make a uniform blend.
2. Dry blend of step 1 was granulated with water.
3. The wet mass of step 2 was dried in fluidized bed dryer.
4. The dried material of step 3 was passed through sieve.
5. Cross-linked polyvinylpyrrolidone, colloidal silicon dioxide and microcrystalline cellulose (rest of the quantity) were sieved. These were then mixed with the dried material of step 4.
6. Magnesium stearate was passed through sieve and mixed with the material of step 5.
7. Lubricated blend of step 6 was compressed.

Examples 2:

Ingredient	Quantity
	(mg/unit)
Oxcarbazepine (Median particle size 15 μm)	600.0
Microcrystalline cellulose	131.2
Hydroxypropyl methyl cellulose	16.8
Sodium lauryl sulphate	20.0
Cross-linked polyvinylpyrrolidone	40.0
Colloidal silicon dioxide	3.2
Magnesium stearate	8.8
Total	800.0

Process:

1. Microcrystalline cellulose (about half the quantity) and hydroxy propyl methylcellulose were sifted through sieve; and mixed with oxcarbazepine for about 10 minutes to make a uniform blend.
2. Sodium lauryl sulphate was dissolved in water and dry blend of step 1 was granulated.
3. The wet mass of step 2 was dried in fluidized bed dryer.
4. The dried material of step 3 was passed through sieve.
5. Cross-linked polyvinyl pyrrolidone, colloidal silicon dioxide and microcrystalline cellulose (rest of the quantity) were sieved. These were then mixed with the dried material of step 4.
6. Magnesium stearate was passed through sieve and mixed with the material of step 5.
7. Lubricated blend of step 6 was compressed.

Example 3:

Ingredient	Quantity
	(mg/unit)
Oxcarbazepine (Median particle size 20.8 μm)	600.0
Microcrystalline cellulose	131.2
Hydroxypropyl methyl cellulose	16.8
Poloxamer 188	20.0
Cross-linked polyvinylpyrrolidone	40.0
Colloidal silicon dioxide	3.2
Magnesium stearate	8.8
Total	800.0

1. Microcrystalline cellulose (about half the quantity) and hydroxy propyl methylcellulose were sifted through sieve; and mixed with oxcarbazepine for about 10 minutes to make a uniform blend.
2. Poloxamer 188 was dispersed in water and dry blend of step 1 was granulated.
3. The wet mass of step 2 was dried in fluidized bed dryer.
4. The dried material of step 3 was passed through sieve.
5. Cross linked polyvinyl pyrrolidone, colloidal silicon dioxide and microcrystalline cellulose (rest of the quantity) were sieved. These were then mixed with the dried material of step 4.
6. Magnesium stearate was passed through sieve and mixed with the material of step 5.
7. Lubricated blend of step 6 was compressed.

Example 4:

Ingredient	Quantity
	(mg/unit)
Oxcarbazepine (Median particle size 20.86 μm)	600
Microcrystalline cellulose	131.2
Hydroxypropyl methyl cellulose	16.8
Sodium lauryl sulphate	20.0
Cross-linked polyvinylpyrrolidone	40.0
Colloidal silicon dioxide	3.2
Magnesium stearate	8.8
Total	800

1. Microcrystalline cellulose (about half the quantity) and hydroxy propyl methylcellulose were sifted through sieve; and mixed with oxcarbazepine for about 10 minutes to make a uniform blend.
2. Sodium lauryl sulphate was dissolved in water and dry blend of step 1 was granulated.
3. The wet mass of step 2 was dried in fluidized bed dryer.
4. The dried material of step 3 was passed through sieve.
5. Cross linked polyvinyl pyrrolidone, colloidal silicon dioxide and microcrystalline cellulose (rest of the quantity) were sieved through #44 BSS. These were then mixed with the dried material of step 4.
6. Magnesium stearate was passed through sieve and mixed with the material of step 5.
7. Lubricated blend of step 6 was compressed.

Example 5:

Ingredient	Quantity
	(mg/unit)
Oxcarbazepine (Median particle size 20.86 μm)	600.0
Microcrystalline cellulose	131.2
Hydroxypropyl methyl cellulose	16.8
Gelucire 44/14	60.0
Cross-linked polyvinylpyrrolidone	40.0
Colloidal silicon dioxide	3.2
Magnesium stearate	8.8
Total	800.0

1. Microcrystalline cellulose (about half the quantity) and hydroxy propyl methylcellulose were sifted through (44 BSS) sieve; and mixed with oxcarbazepine for about 10 minutes to make a uniform blend.
2. Gelucire was dispersed in water and dry blend of step 1 was granulated.
3. The wet mass of step 2 was dried in fluidized bed dryer.
4. The dried material of step 3 was passed through sieve.
5. Cross linked polyvinyl pyrrolidone, colloidal silicon dioxide and microcrystalline cellulose (rest of the quantity) were sieved through #44 BSS. These were then mixed with the dried material of step 4.
6. Magnesium stearate was passed through sieve and mixed with the material of step 5.
7. Lubricated blend of step 6 was compressed.

The oxcarbazepine tablets of Examples 1-5 were subjected to dissolution in 1% sodium lauryl sulphate in water according to the procedure described in the United States Pharmacopoeia XXIII, Apparatus USP II (Paddle) @ 50 rpm. A comparative dissolution

profile with Trileptal® - 600 mg (commercially available tablets of Novartis) is given in Table 1.

Table 1: Dissolution profiles of the oxcarbazepine tablets (prepared by examples 1-5) in comparison with "Trileptal®", in 1% aqueous sodium lauryl sulphate solution at 37°C / 50 rpm using apparatus USP II (Paddle) / 900ml.

Oxcarbazepine Tablets of	10 min.	30 min.	45 min.	60 min.
% drug release for Example 1	62.3	79.0	84.4	85.4
% drug release for Example 2	42.4	80.7	85.2	86.5
% drug release for Example 3	60.8	77.5	80.8	81.0
% drug release for Example 4	23.7	62.9	75.5	82.1
Example 5	39.4	73.3	78.5	81.4
% drug release for Novartis (Trileptal®)	49.8	79.8	82.2	84.2

Examples 6-10:

The tablets of Examples 1-5 were further coated with a coating composition comprising:

Hydroxy propyl cellulose	- 12.0 mg
Talc	- 12.0 mg
Iron oxide yellow	- 0.50 mg
Water	- q.s.

Hydroxy propyl cellulose, talc and iron oxide yellow were dispersed in water and coated onto the tablets of Examples 1-5.

Example 11:

Ingredient	Quantity
	(mg/ 5 ml)
Oxcarbazepine (Median particle size 20.86 μ)	301.81
Microcrystalline cellulose and sodium carboxymethyl cellulose	50.00
Hydroxy ethyl cellulose	150.00
Aerosil 200	25.00
Polyoxyl 8 stearate	10.00
Methyl paraben	9.00
Propyl paraben	1.00
Sorbic acid	1.50
Propylene glycol	250.00
Sodium saccharin	10.00
Ascorbic acid	25.00
Sorbitol solution	1250.00
Purified water	q.s.
Total	Up to 5 ml

1. Avicel RC 591 was dispersed in water using colloid mill.
2. Polyoxyl 8 stearate was added in warm water and added to dispersion of step 1 under homogenization.
3. Sorbitol solution was added to dispersion of step 2.
4. Oxcarbazepine was dispersed in dispersion of step 3.
5. Hydroxy ethylcellulose was dispersed in water and transferred to dispersion of step 4.
6. Methyl paraben, propyl paraben and sorbic acid were dissolved in propylene glycol and transferred to suspension of step 5.

7. Ascorbic acid was dissolved in water and transferred to suspension of step 6.
8. Sodium saccharin was dissolved in water and transferred to suspension of step 7.
9. Aerosil was dispersed in suspension of step 8 and homogenized till a uniform suspension was formed.

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

We Claim:

- 1 1. Oxcarbazepine having a median particle size of from about 14 μm to about 30 μm .
- 1 2. A pharmaceutical dosage form for oral administration comprising oxcarbazepine
2 having a median particle size of from about 14 μm to about 30 μm .
- 1 3. The dosage form of claim 2, wherein the oxcarbazepine has a median particle size
2 of from about 14 μm to about 25 μm .
- 1 4. The dosage form of claim 2, wherein the dosage form comprises a solid or a liquid
2 dosage form.
- 1 5. The dosage form of claim 4, wherein the solid dosage form comprises one or more
2 of a tablet, a capsule, and a granulate.
- 1 6. The dosage form of claim 5, wherein the tablet dosage form is coated.
- 1 7. The dosage form of claim 5, further comprising one or more pharmaceutically
2 acceptable excipients comprising one or more of surfactants, diluents, binders,
3 disintegrants, lubricants, glidants, and coloring agents.
- 1 8. The dosage form of claim 4, wherein the liquid dosage form comprises one or both
2 of a solution or a suspension.
- 1 9. The dosage form of claim 8, further comprising one or more pharmaceutically
2 acceptable excipients comprising one or more of solvents, antioxidants, suspending agents,
3 preservatives, surfactants, sweeteners, and flavoring agents.
- 1 10. A process for preparing a solid dosage form of oxcarbazepine, the process
2 comprising:
3 mixing oxcarbazepine having a median particle size of from about 14 μm to about
4 30 μm with other pharmaceutical excipients to form a blend; and
5 forming the blend into a solid dosage form.
- 1 11. The process of claim 10, wherein forming the blend into a solid dosage form
2 comprises forming a tablet, capsule or granulate.

- 1 12. The process of claim 10, wherein the mixing comprises dry granulation, wet
2 granulation or direct compression.
- 1 13. The process of claim 12, wherein the wet granulation is carried out with a
2 granulating fluid.
- 1 14. The process of claim 12, wherein the wet granulation is carried out with a solution
2 or dispersion of a surfactant.
- 1 15. The process of claim 12, wherein the wet granulation is carried out with a solution
2 or dispersion of a binder.
- 1 16. The process of claim 12, wherein the dry granulation is carried out by roller
2 compactor or slugging.
- 1 17. A process for preparing a liquid dosage form of oxcarbazepine, the process
2 comprising:
3 a) dispersing a suspending agent in water;
4 b) dispersing the oxcarbazepine having a median particle size of from about 14 μm
5 to about 30 μm in the dispersion of step a); and
6 c) homogenizing.
- 1 18. The process of claim 17, wherein the suspending agent comprises one or more of
2 polysaccharides, a mixture of cellulose and xanthan gum, a mixture of polyethylene glycol
3 and sodium carboxymethyl cellulose, a mixture of xanthan gum and pregelatinized starch,
4 a mixture of microcrystalline cellulose and sodium carboxymethyl cellulose, and dispersed
5 silicon dioxide.
- 1 19. The process of claim 17, further comprising one or more pharmaceutically
2 acceptable excipients comprising one or more of solvents, antioxidants, preservatives,
3 surfactants, sweeteners, and flavoring agents.
- 1 20. A method of treating partial seizures in adults with epilepsy and as an adjunct
2 therapy for treating partial seizures in children ages 4-16 with epilepsy, the method
3 comprising orally administering to an adult or a child in need thereof a dosage form
4 comprising oxcarbazepine having a median particle size of from about 14 μm to about 30
5 μm .

INTERNATIONAL SEARCH REPORT

International application No
/IB2005/003168

A. CLASSIFICATION OF SUBJECT MATTER

A61K31/55 A61K9/16 A61K9/20 A61K9/28 A61K9/48
A61K9/08 A61K9/10 A61P25/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/094774 A (RANBAXY LABORATORIES LIMITED; SEHGAL, ASHISH; TREHAN, ANUPAM; ARORA, V) 28 November 2002 (2002-11-28) cited in the application	1,2, 4-15,20
Y	the whole document	1-20
X	US 2004/142033 A1 (FRANKE HANSHERMANN ET AL) 22 July 2004 (2004-07-22)	1-7, 10-13,20
Y	page 2, paragraph 43 - page 3, paragraph 110 page 4, paragraphs 112-118,130	1-20
	----- -/--	



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 February 2006

Date of mailing of the international search report

28/02/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

HOUYVET, C

INTERNATIONAL SEARCH REPORT

International application No
/IB2005/003168

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/32183 A (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H; LANG,) 10 May 2001 (2001-05-10) page 4, paragraph 5 - page 5, paragraphs 1,3,5,6 page 6, paragraphs 5,6 page 7, paragraphs 1,2,5 page 8, paragraph 2; example 1 -----	1-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2005/003168

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 20 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

/IB2005/003168

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02094774	A	28-11-2002	BR 0209845 A	24-08-2004
			CN 1522140 A	18-08-2004
			EP 1395247 A2	10-03-2004
			JP 2004529966 T	30-09-2004
			MX PA03010549 A	27-05-2004
			US 2004197402 A1	07-10-2004
			ZA 200309289 A	01-09-2004
US 2004142033	A1	22-07-2004	AU 2003240654 A1	19-12-2003
			BR 0311327 A	22-02-2005
			CA 2485932 A1	11-12-2003
			WO 03101430 A1	11-12-2003
			EP 1509207 A1	02-03-2005
			HR 20041193 A2	30-06-2005
			JP 2005528429 T	22-09-2005
			MD 20040296 A	31-05-2005
			US 2004185095 A1	23-09-2004
WO 0132183	A	10-05-2001	AU 777705 B2	28-10-2004
			AU 1997801 A	14-05-2001
			BR 0015188 A	05-11-2002
			CA 2388609 A1	10-05-2001
			CN 1407894 A	02-04-2003
			CZ 20021529 A3	14-08-2002
			EP 1242091 A2	25-09-2002
			HU 0203556 A2	28-02-2003
			JP 2003514780 T	22-04-2003
			MX PA02004389 A	02-09-2002
			NO 20022058 A	27-06-2002
			NZ 518378 A	29-10-2004
			PL 366314 A1	24-01-2005
			SK 5842002 A3	06-08-2002
			TR 200200951 T2	21-01-2003
			ZA 200203394 A	29-07-2003